Gilead Sciences, Inc. (GILD)
146.76
+0.64
(+0.44%)
USD |
NASDAQ |
Aug 24, 16:00
146.50
-0.26
(-0.18%)
After-Hours: 20:00
Gilead Sciences Enterprise Value : 202.61B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 202.61B |
| August 20, 2026 | 199.29B |
| August 19, 2026 | 204.45B |
| August 18, 2026 | 199.29B |
| August 17, 2026 | 193.68B |
| August 14, 2026 | 192.98B |
| August 13, 2026 | 192.71B |
| August 12, 2026 | 189.89B |
| August 11, 2026 | 189.77B |
| August 10, 2026 | 186.41B |
| August 07, 2026 | 186.59B |
| August 06, 2026 | 183.68B |
| August 05, 2026 | 184.79B |
| August 04, 2026 | 189.13B |
| August 03, 2026 | 184.04B |
| July 31, 2026 | 182.87B |
| July 30, 2026 | 184.20B |
| July 29, 2026 | 186.00B |
| July 28, 2026 | 187.97B |
| July 27, 2026 | 183.26B |
| July 24, 2026 | 181.75B |
| July 23, 2026 | 183.68B |
| July 22, 2026 | 183.03B |
| July 21, 2026 | 182.96B |
| July 20, 2026 | 186.59B |
| Date | Value |
|---|---|
| July 17, 2026 | 187.92B |
| July 16, 2026 | 190.43B |
| July 15, 2026 | 184.72B |
| July 14, 2026 | 182.66B |
| July 13, 2026 | 184.35B |
| July 10, 2026 | 182.40B |
| July 09, 2026 | 188.62B |
| July 08, 2026 | 189.83B |
| July 07, 2026 | 190.50B |
| July 06, 2026 | 182.13B |
| July 02, 2026 | 184.19B |
| July 01, 2026 | 177.61B |
| June 30, 2026 | 178.07B |
| June 29, 2026 | 169.17B |
| June 26, 2026 | 171.10B |
| June 25, 2026 | 166.08B |
| June 24, 2026 | 167.72B |
| June 23, 2026 | 167.59B |
| June 22, 2026 | 167.36B |
| June 18, 2026 | 165.98B |
| June 17, 2026 | 168.08B |
| June 16, 2026 | 170.29B |
| June 15, 2026 | 166.65B |
| June 12, 2026 | 168.26B |
| June 11, 2026 | 168.60B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Vertex Pharmaceuticals, Inc. | 132.96B |
| AbbVie, Inc. | 532.50B |
| Regeneron Pharmaceuticals, Inc. | 80.94B |
| Amgen, Inc. | 280.82B |
| Biogen, Inc. | 39.09B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -10.50B |
| Revenue (Quarterly) | 7.821B |
| Total Expenses (Quarterly) | 18.32B |
| EPS Diluted (Quarterly) | -8.444 |
| Gross Profit Margin (Quarterly) | 79.81% |
| Profit Margin (Quarterly) | -134.2% |
| Earnings Yield | -1.81% |
| Operating Earnings Yield | 6.50% |
| Normalized Earnings Yield | 3.238 |